Navigation Links
Effectiveness of progesterone in reducing preterm births may be altered by genetic predisposition
Date:1/29/2009

SAN DIEGO, CA, JAN. 30, 2009 New research that may explain why taking progesterone to prevent preterm birth is only effective for some women was unveiled today at the 29th Annual Society for Maternal-Fetal Medicine (SMFM) meeting The Pregnancy Meeting.

The drug, 17 alpha-hydroxyprogesterone caproate (or 17P), a synthetic form of the progesterone hormone naturally produced during pregnancy, has been demonstrated in clinical trials to prevent some recurrent preterm births but not all.

"This study helps strengthen the theory that genetic variation in the human progesterone receptor plays an important role in the effectiveness of 17P," states Tracy Manuck, M.D., study author and SMFM member.

Women who have a spontaneous preterm delivery are at greatly increased risk of preterm delivery in subsequent pregnancies. Preterm birth is a leading cause of infant death in the United States and babies who survive face serious lifelong health problems. More than 543,000 babies are born too soon each year and recent federal statistics show that the nation's preterm birth rate has risen to 12.8 percent -- a 36 percent increase since the early 1980s.

"Dr. Manuck's research gives us a tantalizing clue as to why 17P works for some women, but not for others," said Alan R. Fleischman, M.D., senior vice president and medical director of the March of Dimes. "With further research along these lines, we hope to someday be able to prevent preterm birth from happening in the first place by screening women before they get pregnant, and identifying those whose babies could get a healthy start in life with the help of 17P."

The research, which was sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Unit Network and the University of Utah, assessed whether women with genetic variations known as single nucleotide polymorphisms (SNPs) in the human progesterone receptor gene we
'/>"/>

Contact: Elizabeth Lynch
elynch@marchofdimes.com
914-997-4286
March of Dimes Foundation
Source:Eurekalert

Page: 1 2

Related biology news :

1. UC health news: molecular pathway may predict chemotherapy effectiveness
2. Socioeconomic position associated with effectiveness of HIV drugs
3. MIT model could improve some drugs effectiveness
4. Trial seeks genetic fingerprint for predicting drug effectiveness
5. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
6. Poll Shows Strong Doubts About Effectiveness of Federal Employment Verification System
7. New studies on the Mediterranean diet confirm its effectiveness for chronic disease prevention
8. RNA molecules, delivery system improve vaccine responses, effectiveness
9. New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning
10. Research shows cells inactive state is critical for effectiveness of cancer treatment
11. Corazonas Foods and Brandeis University partner to create cholesterol-reducing snacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... National Institutes of Health is making available approximately ... for graduate students and postdoctoral scholars to prepare ... that could take them outside of conventional academic ... Broadening Experience in Scientific Training (BEST) awards are ...
... Geosphere has posted additions to several themed issues: ... Geodynamics and Consequences of Lithospheric Removal in the Sierra ... Snake River Plain-Yellowstone Region and Adjacent Areas; Origin and ... other articles cover terrestrial laser scanning and the earthquake ...
... University scientist Bryan Venters, Ph.D., has shed new light ... begun to explore a possible new approach to treating ... of Molecular Physiology and Biophysics who further developed the ... of Frank Pugh, Ph.D., at Pennsylvania State University before ...
Cached Biology News:NIH announces awards to strengthen the biomedical research workforce 2NIH announces awards to strengthen the biomedical research workforce 3Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 2Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 3Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 4Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 5Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 6Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 7Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 8Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 9Study helps bring genome's 'dark matter' into light 2
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... American and European fidaxomicin Phase 3 clinical trials ... (CDI) was presented at the 50th Annual Interscience ... Boston. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) ...
... CRANBURY, N.J., Sept. 14 Innophos Holdings, Inc. (Nasdaq: ... today announced that Randy Gress, Chief Executive Officer, will address ... September 30, 2010 at 8:00 a.m. (Eastern Time).   ... event, please go to www.innophos.com Investor Relations Events ...
Cached Biology Technology:Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 2Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 4Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 5Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 6Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 7Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 8Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 2Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 3Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 4Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 5Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 6Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 7
Vybrant® Multidrug Resistance Assay Kit...
...
... The CultureWell cell culture systems ... cultured cells for staining and imaging. ... preassembled with standard optical-quality coverslips in ... is provided sterile and ready to ...
... product contains 5 ml of DETACHaBEAD Mouse ... mouse CD4+ T cells from Dynabeads Mouse ... CD4+ T cells from Dynabeads Mouse CD4 ... are suitable for any downstream application including ...
Biology Products: